Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;14(3):3302-3308.
doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18.

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only

Linda Hertlein  1 , Johanna Rath  1 , Christine Zeder-Göss  1 , Sophie Fürst  1 , Daniela Bayer  1 , Fabian Trillsch  1 , Sven Mahner  1 , Alexander Burges  1 , Udo Jeschke  1
Affiliations

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only

Linda Hertlein et al. Oncol Lett. 2017 Sep.

Abstract

The present study aimed to identify differences in protein expression in cases of endometrioid endometrial cancer (EEC) with and without coexisting adenomyosis uteri (AM), and to evaluate the histopathological and prognostic distinctions. The total cohort included 22 patients in Group A (patients with concomitant AM and EEC) and 35 patients in Group B (patients affected only by EEC). Evaluation of the following factors was performed: Tumour grade, International Federation of Gynaecology and Obstetrics (FIGO) stage, survival, and expression of estrogen receptor β (ERβ), glycodelin and inhibin βB. Group A (AM and EEC) was associated with a lower tumour grade (G1, 90.9 vs. 45.7%; P=0.001) and a lower FIGO stage (FIGO stage I, 100 vs. 80%; P=0.002) compared with Group B (EEC only). In the survival analysis, Group A was associated with a significantly higher 5-year survival rate (95 vs. 82%; P=0.024) than Group B. In addition, the expression of ERβ in Group A was significantly higher (P<0.001), whereas the expression of glycodelin is significantly lower (P=0.028), compared with Group B. The results of the present study indicate that the presence of AM in cases of EEC may be a positive prognostic factor.

Keywords: adenomyosis uteri; endometrioid endometrial cancer; estrogen receptor β; glycodelin; inhibin βB.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Association between grade and presence of adenomyosis uteri in patients with endometrioid endometrial cancer.
Figure 2.
Figure 2.
Survival curves of the endometrioid endometrial cancer patients with and without adenomyosis uteri (P=0.024).
Figure 3.
Figure 3.
ERβ expression in Group B (patients with endometrioid endometrial cancer only). Representative photomicrographs of ERβ immunohistochemical staining are shown (immunoreactivity score, 0). ERβ, estrogen receptor β.
Figure 4.
Figure 4.
ERβ expression in Group A (patients with endometrioid endometrial cancer and adenomyosis uteri). Representative microphotographs of ERβ immunohistochemical staining are shown (immunoreactivity score, 2). ERβ, estrogen receptor β.
Figure 5.
Figure 5.
Glycodelin expression in Group A (patients with endometrioid endometrial cancer and adenomyosis uteri). Representative microphotographs of glycodelin immunohistochemical staining are shown (immunoreactivity score, 4).
Figure 6.
Figure 6.
Glycodelin expression in Group B (patients with endometrioid endometrial cancer only). Representative microphotographs of glycodelin immunohistochemical staining are shown (immunoreactivity score, 6).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35:649–662. doi: 10.1016/j.humpath.2004.02.007. - DOI - PubMed
    1. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20:511–521. doi: 10.1016/j.bpobgyn.2006.01.016. - DOI - PubMed
    1. Kucera E, Hejda V, Dankovcik R, Valha P, Dudas M, Feyereisl J. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2011;32:182–184. - PubMed
    1. Ismiil N, Rasty G, Ghorab Z, Nofech-Mozes S, Bernardini M, Ackerman I, Thomas G, Covens A, Khalifa MA. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol. 2007;11:252–257. doi: 10.1016/j.anndiagpath.2006.08.011. - DOI - PubMed